Emyria Ltd (EMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emyria Ltd (EMD) has a cash flow conversion efficiency ratio of -0.316x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.67 Million ≈ $-1.18 Million USD) by net assets (AU$5.31 Million ≈ $3.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EMD net asset quality index to measure how much of total assets are equity-financed.
Emyria Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Emyria Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EMD cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Emyria Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emyria Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hudson Acquisition I Corp. Common Stock
NASDAQ:HUDA
|
0.012x |
|
Sangji Caelum Inc
KQ:042940
|
-0.054x |
|
Fusemachines Inc. Common stock
NASDAQ:FUSE
|
1.481x |
|
Niche Capital Emas Holdings
KLSE:7139
|
0.013x |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
0.658x |
|
CryoCell International Inc
NYSE MKT:CCEL
|
-0.171x |
|
KPS Consortium Bhd
KLSE:9121
|
0.004x |
|
Foremost Lithium Resource & Technology Ltd. Common stock
NASDAQ:FMST
|
-0.050x |
Annual Cash Flow Conversion Efficiency for Emyria Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Emyria Ltd from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Emyria Ltd (EMD) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.31 Million ≈ $3.75 Million |
AU$-2.70 Million ≈ $-1.91 Million |
-0.510x | +71.14% |
| 2024-06-30 | AU$2.43 Million ≈ $1.72 Million |
AU$-4.28 Million ≈ $-3.03 Million |
-1.767x | -218.22% |
| 2023-06-30 | AU$6.79 Million ≈ $4.81 Million |
AU$-3.77 Million ≈ $-2.67 Million |
-0.555x | +35.34% |
| 2022-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-5.43 Million ≈ $-3.84 Million |
-0.859x | -56.53% |
| 2021-06-30 | AU$7.18 Million ≈ $5.08 Million |
AU$-3.94 Million ≈ $-2.79 Million |
-0.549x | +53.40% |
| 2020-06-30 | AU$3.78 Million ≈ $2.68 Million |
AU$-4.45 Million ≈ $-3.15 Million |
-1.177x | +77.33% |
| 2019-06-30 | AU$499.54K ≈ $353.46K |
AU$-2.59 Million ≈ $-1.83 Million |
-5.191x | -69937.67% |
| 2018-06-30 | AU$2.81 Million ≈ $1.99 Million |
AU$-20.82K ≈ $-14.73K |
-0.007x | -- |
About Emyria Ltd
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-… Read more